Last reviewed · How we verify
vaccinated with Sabin IPV
Sabin IPV (inactivated polio vaccine) stimulates the immune system to produce antibodies against all three poliovirus serotypes, preventing poliomyelitis infection.
Sabin IPV (inactivated polio vaccine) stimulates the immune system to produce antibodies against all three poliovirus serotypes, preventing poliomyelitis infection. Used for Prevention of poliomyelitis (all three poliovirus serotypes).
At a glance
| Generic name | vaccinated with Sabin IPV |
|---|---|
| Sponsor | Zhejiang Provincial Center for Disease Control and Prevention |
| Drug class | vaccine |
| Target | poliovirus serotypes 1, 2, and 3 |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Sabin IPV is an inactivated (killed) poliovirus vaccine containing chemically inactivated strains of poliovirus types 1, 2, and 3. When administered, it triggers both humoral (antibody) and cellular immune responses without risk of vaccine-strain disease. The vaccine prevents infection by inducing neutralizing antibodies that block viral entry and replication.
Approved indications
- Prevention of poliomyelitis (all three poliovirus serotypes)
Common side effects
- Local injection site reactions (pain, redness, swelling)
- Fever
- Myalgia
Key clinical trials
- Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines (PHASE1)
- Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China (PHASE4)
- A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates (PHASE2)
- A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China. (PHASE4)
- A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania (PHASE4)
- To Evaluate the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPV (PHASE4)
- Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines (PHASE3)
- Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: